<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125254</url>
  </required_header>
  <id_info>
    <org_study_id>000002</org_study_id>
    <nct_id>NCT01125254</nct_id>
  </id_info>
  <brief_title>Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major</brief_title>
  <acronym>AnloThal</acronym>
  <official_title>Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the use of amlodipine, a drug that blocks the uptake of
      calcium into cells, in the prevention and treatment of iron overload in patients with
      thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and
      other organs, blocking these channels might help to prevent the accumulation of iron in these
      tissues. The study will follow 10 patients with thalassemia major: 5 will openly receive
      amlodipine and 5 will serve as controls, not receiving any additional drugs. Patients will be
      monitored through one year with an additional year of follow up after the group using
      amlodipine stops its use. Monitoring will occur through the measurement of blood ferritin as
      well as live and heart T2* by MRI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardium T2*</measure>
    <time_frame>12 months</time_frame>
    <description>Heart T2* by MRI at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver T2*</measure>
    <time_frame>24 months</time_frame>
    <description>Liver T2* by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart volumes</measure>
    <time_frame>24 months</time_frame>
    <description>Diastolic and systolic volumes by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fraction</measure>
    <time_frame>24 months</time_frame>
    <description>LVEF by MRI every 6 months for 2 years. First year with active treatment; second year with withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin</measure>
    <time_frame>24 months</time_frame>
    <description>Serum ferritin every 6 months for 2 years. First year with active treatment; second year with withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardium T2*</measure>
    <time_frame>6-18-24 months</time_frame>
    <description>Heart T2* by MRI every 6 months until 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amlodipine 5mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5mg po for 12 months</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with thalassemia major over 6 years of age in use of iron chelating therapy.

        Exclusion Criteria:

          -  pregnancy;

          -  advanced heart failure with NYHA III/IV or LVEF &lt; 35%;

          -  formal contra-indications to an MRI study;

          -  patient with advanced heart block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliano L Fernandes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>January 2, 2015</last_update_submitted>
  <last_update_submitted_qc>January 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Juliano de Lara Fernandes</investigator_full_name>
    <investigator_title>Research Physician</investigator_title>
  </responsible_party>
  <keyword>thalassemia major</keyword>
  <keyword>calcium channel blockade</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

